A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.

Trial Details

NCT ID
NCT07133425
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • SAR445877
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Eligibility Criteria
  • Ability to understand and willingness to sign informed consent form (ICF) prior to initiation of the study and any study procedures.
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SAR445877 in participants \<18 years of age, children …
  • Participants with histologically documented locally advanced or metastatic NSCLC who have had disease progression after treatment with all availabl…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →